{
  "resourceType": "RegulatedAuthorization",
  "id": "basic-drug-auth",
  "text": {
    "status": "generated",
    "div": "\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cdiv\u003e\u003cp\u003eResource \u0026quot;basic-drug-auth\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca\u003eMedicinalProductDefinition/equilidem\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: Regulatory Drug Marketing Approval \u003cspan\u003e ()\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatus\u003c/b\u003e: active \u003cspan\u003e ([not stated]#active)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003estatusDate\u003c/b\u003e: 2016-01-01\u003c/p\u003e\u003cp\u003e\u003cb\u003eholder\u003c/b\u003e: \u003ca\u003eOrganization/EqlidrugCo: EquiliDrugCo Holdings Inc.\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eregulator\u003c/b\u003e: \u003ca\u003eOrganization/FDA: FDA\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e"
  },
  "subject": [
    {
      "reference": "MedicinalProductDefinition/equilidem"
    }
  ],
  "type": {
    "text": "Regulatory Drug Marketing Approval"
  },
  "status": {
    "coding": [
      {
        "code": "active"
      }
    ]
  },
  "statusDate": "2016-01-01",
  "holder": {
    "reference": "Organization/EqlidrugCo",
    "display": "EquiliDrugCo Holdings Inc."
  },
  "regulator": {
    "reference": "Organization/FDA",
    "display": "FDA"
  },
  "meta": {
    "tag": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-ActReason",
        "code": "HTEST",
        "display": "test health data"
      }
    ]
  }
}